Skip to main content

Table 3 Recommendations of TURBT and re-TURBTa

From: Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations

Guideline ID

TURBT

Re-TURBT

Be recommended

Adequate resection with muscle in specimen

No muscle in original specimen

Ta

T1

Interval between TURBT and Re-TURBT

SOR/LOE

G&S

SOR/LOE

G&S

SOR/LOE

G&RS

SOR/LOE

G

SOR/LOE

Interval

SOR/LOE

ESMO, 2014 [8]

−/−

A/I

−/−

High-risk

B/II-III

B/II-III

−/−

NICE, 2015 [9]b

−/−

A/low-very low

A/low-very low

High-risk

A/low-very low

A/low-very low

6

A/low-very low

CUA, 2015 [10]

−/−

A/−

Only T1

A/−

HG

C/−

C/−

2–6

A/−

AUA/SUO, 2016 [3]

−/−

−/−

Strong/B

High-risk, HG

Moderate/C

Strong/B

6

−/−

JUA, 2016 [11]

A/−

−/−

−/−

−/−

HG

A/−

−/−

EAU, 2018 [12]

Strong/1b

Except for TaG1/LG

Strong/1b

Except for TaG1/LG and primary CIS

Strong/1b-3

−/−

Strong/1b-3

2–6

Weak/3

ICUD/SIU, 2018 [13]

C/3

−/−

B/2

HG

C/3

B/2

6

B-C/2–3

CRHA/CPAM, 2018 [14]

A/4

Except for TaG1/LG

A/4

A/4

G3/HG

A/4

A/4

6

A/4

NCCN, 2019 [15]c

−/−

Except for TaLG

B/2A

Only HG

B/2A

> 3 cm or multi-focal

B/2A

B/2A

6

B/2A

  1. G Grading, S Staging, RS Risk stratification, HG High grade, CIS Carcinoma in situ
  2. a The SOR and LOE are presented as “SOR/LOE”. “-” indicates that the recommendation or evidence was not presented
  3. b To simplify the table, we used “A” and “B” instead of “should/should not/offer/do not offer/refer/advise” or “consider” for presenting SOR
  4. c To simplify the table, we used “A” and “B”, “C” instead of “preferred intervention”, “other recommended intervention”, or “useful in certain circumstances” for presenting SOR